Literature DB >> 6834388

Design, synthesis, and testing of antisickling agents. 2. Proline derivatives designed for the donor site.

D J Abraham, M Mokotoff, L Sheh, J E Simmons.   

Abstract

We have used a three-dimensional model of deoxyhemoglobin to design potential antisickling agents with an intended binding site in the vicinity of the beta-6 mutation (donor site). Two proline derivatives, (4S)-1-butyryl-4-[(carboxymethyl)amino]-L-proline (9a) and its 1-benzoyl analogue (9b), were designed to interact, via ionic or hydrogen bonds, with polar residues beta His-2, beta Thr-4, and beta Lys-132 of hemoglobin S (HbS). Two other proline derivatives containing a salicylate leaving group, (4S)-1-butyryl-4-[(carboxymethyl)methylamino]-L-proline, 2-ester with salicyclic acid (14a), and its 1-benzoyl analogue (14b), were designed to bind covalently to beta Lys-132, as well as to interact with beta His-2 and beta Thr-4 via ionic and hydrogen bonds. This paper describes the synthesis of these agents, beginning with natural L-hydroxyproline methyl ester, and the testing of their ability to increase or decrease the solubility of dHbS by using a standard solubility assay. The covalent derivatives 14a,b were found to be inactive, while the noncovalent compounds 9a,b showed weak antigelling activity, below that observed for phenylalanine. The presence of only weak activity does not invalidate this approach, since only one structural parameter has been investigated.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6834388     DOI: 10.1021/jm00358a017

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

1.  Photochemical energy conversion in a helical oligoproline assembly.

Authors:  D G McCafferty; D A Friesen; E Danielson; C G Wall; M J Saderholm; B W Erickson; T J Meyer
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

Review 2.  Modulating hemoglobin allostery for treatment of sickle cell disease: current progress and intellectual property.

Authors:  Piyusha P Pagare; Aref Rastegar; Osheiza Abdulmalik; Abdelsattar M Omar; Yan Zhang; Andrew Fleischman; Martin K Safo
Journal:  Expert Opin Ther Pat       Date:  2021-11-01       Impact factor: 6.714

3.  Privileged substructures for anti-sickling activity via cheminformatic analysis.

Authors:  Chuleeporn Phanus-Umporn; Watshara Shoombuatong; Veda Prachayasittikul; Nuttapat Anuwongcharoen; Chanin Nantasenamat
Journal:  RSC Adv       Date:  2018-02-07       Impact factor: 4.036

Review 4.  Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin.

Authors:  Martin K Safo; Gregory J Kato
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-21       Impact factor: 3.722

Review 5.  Rational Drug Design of Peptide-Based Therapies for Sickle Cell Disease.

Authors:  Olujide O Olubiyi; Maryam O Olagunju; Birgit Strodel
Journal:  Molecules       Date:  2019-12-12       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.